Compare Stocks

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APS Aptose Biosciences	C$1.75	C$2.20	C$1.71 ▼ C$11.40	C$27.49M	1.44	8,872 shs	10,978 shs
PRTC PureTech Health	$26.94	$26.29	$17.08 ▼ $34.00	$727.25M	1.23	3,434 shs	228 shs

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APS Aptose Biosciences	0.00%	-7.89%	-12.94%	-40.27%	+157.35%
PRTC PureTech Health	0.00%	-3.56%	-5.08%	+14.52%	-2.05%

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APS Aptose Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	0.1165 of 5 stars	0.0	3.0	0.0	0.0	1.8	0.0	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APS Aptose Biosciences	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APS Aptose Biosciences	N/A	N/A	C$1.09 per share	1.60	C$1.03 per share	N/A
PRTC PureTech Health	$15.62M	46.56	N/A	N/A	$19.64 per share	1.37

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APS Aptose Biosciences	-C$51.21M	-C$10.49	N/A	∞	N/A	N/A	-225.00%	-102.23%	5/13/2024 (Estimated)
PRTC PureTech Health	-$50.35M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	4/26/2024 (Estimated)

Latest OXB, APS, and PRTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/26/2024	Q4 2023	APS Aptose Biosciences	-C$1.98	-C$1.96	+C$0.02	-C$1.96	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APS Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APS Aptose Biosciences	14.27	0.78	5.41
PRTC PureTech Health	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
APS Aptose Biosciences	9.80%
PRTC PureTech Health	0.04%

Insider Ownership

Company	Insider Ownership
APS Aptose Biosciences	20.20%
PRTC PureTech Health	5.30%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
APS Aptose Biosciences	31	15.71 million	N/A	Not Optionable
PRTC PureTech Health	111	27.00 million	25.56 million	Not Optionable

OXB, APS, and PRTC Headlines

Source	Headline
	PureTech Health: Notice of Results businesswire.com - April 18 at 2:00 AM
	PureTech Health (NASDAQ:PRTC) Shares Gap Up to $25.48 marketbeat.com - April 17 at 2:15 PM
	PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis finance.yahoo.com - April 16 at 7:49 AM
	PureTech Health (NASDAQ:PRTC) Shares Gap Down to $27.93 americanbankingnews.com - April 14 at 2:52 AM
	PureTech Health (NASDAQ:PRTC) Sees Large Volume Increase americanbankingnews.com - April 12 at 5:26 AM
	US FDA hands fast track to PureTech head and neck cancer treatment lse.co.uk - April 11 at 8:26 AM
	PureTech's LYT-200 Receives FDA Fast Track Designation For Treatment Of Head & Neck Cancers markets.businessinsider.com - April 11 at 8:26 AM
	PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers businesswire.com - April 11 at 7:00 AM
	PureTech Health (NASDAQ:PRTC) Sees Unusually-High Trading Volume marketbeat.com - April 10 at 12:36 PM
	PureTech launches Seaport and changes CEO thepharmaletter.com - April 9 at 1:47 PM
	PureTech launches Seaport, hoping to create Karuna 2.0 biopharmadive.com - April 9 at 1:47 PM
	PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions businesswire.com - April 9 at 2:00 AM
	PureTech Health (NASDAQ:PRTC) Trading Down 5.9% marketbeat.com - April 5 at 1:28 PM
	PureTech Health (NASDAQ:PRTC) Sets New 52-Week High at $34.00 marketbeat.com - April 4 at 5:53 PM
	PureTech Health (NASDAQ:PRTC) Shares Gap Down to $30.00 marketbeat.com - April 2 at 11:18 AM
	PureTech Health (PRTC) is on the Move, Here's Why the Trend Could be Sustainable zacks.com - April 2 at 9:51 AM
	PureTech Health (NASDAQ:PRTC) Shares Gap Up to $28.50 marketbeat.com - April 1 at 5:30 PM
	PureTech Health (NASDAQ:PRTC) Shares Gap Down to $29.40 marketbeat.com - March 27 at 12:23 PM
	PureTech rewards shareholders with $100 million tender offer thepharmaletter.com - March 21 at 8:37 AM
	Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion businesswire.com - March 18 at 9:52 AM
	PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia finance.yahoo.com - March 13 at 8:41 AM
	AKLI Mar 2024 3.000 call finance.yahoo.com - February 28 at 1:37 PM
	PureTech notes positive results from Shionogi's EndeavorRx ADHD trial lse.co.uk - February 27 at 7:53 AM
	PureTech to Present at Two Upcoming Investor Conferences finance.yahoo.com - February 27 at 7:53 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
5 Top-Rated Dividend Stocks With Double-Digit Upside
March 25, 2024 11:19 AM
View 5 Top-Rated Dividend Stocks With Double-Digit Upside
Consumer Sentiment Highest Since 2021, 3 Stocks Leading the Way
April 1, 2024 9:25 AM
View Consumer Sentiment Highest Since 2021, 3 Stocks Leading the Way

All Headlines

Company Descriptions

Aptose Biosciences

TSE:APS

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

PureTech Health

NASDAQ:PRTC

PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial